Skip to Content

Aminophylline Pregnancy and Breastfeeding Warnings

Aminophylline is also known as: Phyllocontin, Truphylline

Aminophylline Pregnancy Warnings

Aminophylline (theophylline) has been assigned to pregnancy category C by the FDA. Animal studies of theophylline have revealed evidence of embryolethality and teratogenicity. There are no controlled data in human pregnancy. Aminophylline is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.

The Collaborative Perinatal Project monitored 193 women with first trimester exposure to theophylline or aminophylline and found no increased risk of malformations. Cord serum concentrations and infant serum concentrations have been reported to approximate the mother's serum concentrations immediately following birth. In 12 mothers receiving aminophylline, maternal serum, cord serum, and infant serum theophylline concentrations averaged 10 mcg/mL at the time of delivery. Jitteriness, irritability, and vomiting have been reported in infants of mothers maintained on theophylline or aminophylline prior to delivery. Apnea has been reported in an infant born after 37.5 weeks gestation to a mother who had been maintained on theophylline throughout pregnancy for asthma. At approximately 48 hours after birth, the infant's serum theophylline concentration was 15 mcg/mL. The infant was placed on theophylline when the concentration measured 2 mcg/mL. Apnea resolved when the theophylline concentration reached 17 mcg/mL. The pharmacokinetics of theophylline have been studied in women during pregnancy. Studies throughout pregnancy have noted a significant decrease in the clearance of theophylline during the third trimester. The clearance was only slightly decreased during the first and second trimester. The plasma protein binding of theophylline also has been shown to decrease in the later stages of pregnancy. It is important to closely monitor the theophylline serum concentration and the patient for signs of toxicity during pregnancy.

See references

Aminophylline Breastfeeding Warnings

Aminophylline (theophylline) is excreted in human milk and may cause irritability or other signs of mild toxicity. The concentration of theophylline in breast milk is approximately equivalent to the maternal serum concentration. The manufacturer states that serious adverse effects in the infant are unlikely unless the mother has toxic serum theophylline concentrations. The American Academy of Pediatrics considers theophylline to be compatible with breast-feeding.

In a study of five women given aminophylline, theophylline was detected in milk with a milk:serum ratio of 0.61 to 0.87. The peak milk concentration occurred between one and three hours after ingestion of the dose. Irritability was reported in one infant whose mother took aminophylline. Adverse effects were not reported in the infants of the other women participating in this study. Exposure to the infant can be minimized by nursing prior to administration of aminophylline to avoid peak milk concentrations.

See references

References for pregnancy information

  1. Weinstein AM, Dubin BD, Podleski WK, Spector SL, Farr RS "Asthma and pregnancy." JAMA 241 (1979): 1161-5
  2. Heinonen O, Slone D, Shapiro S; Kaufman DW ed. "Birth Defects and Drugs in Pregnancy." Littleton, MA: Publishing Sciences Group, Inc. (1977): 297
  3. Carter BL, Driscoll CE, Smith GD "Theophylline clearance during pregnancy." Obstet Gynecol 68 (1986): 555-9
  4. "Product Information. Theo-Dur (theophylline)." Schering Laboratories, Kenilworth, NJ.
  5. Labovitz E, Spector S "Placental theophylline transfer in pregnant asthmatics." JAMA 247 (1982): 786-8
  6. Turner ES, Greenberger PA, Patterson R "Management of the pregnant asthmatic patient." Ann Intern Med 6 (1980): 905-10
  7. Ron M, Hochner-Celnikier D, Menczel J, Palti Z, Kidroni G "Maternal-fetal transfer of aminophylline." Acta Obstet Gynecol Scand 63 (1984): 217-8
  8. Horowitz DA, Jablonski W, Mehta KA "Apnea associated with theophylline withdrawal in a term neonate." Am J Dis Child 136 (1982): 73-4
  9. Frederiksen MC, Ruo TI, Chow MJ, Atkinson AJ, Jr "Theophylline pharmacokinetics in pregnancy." Clin Pharmacol Ther 40 (1986): 321-8
  10. Arwood LL, Dasta JF, Friedman C "Placental transfer of theophylline: two case reports." Pediatrics 63 (1979): 844-6
  11. Hernandez E, Angell CS, Johnson JW "Asthma in pregnancy: current concepts." Obstet Gynecol 55 (1980): 739-43
  12. Yeh TF, Pildes RS "Transplacental aminophylline toxicity in a neonate." Lancet 1 (1977): 910
  13. Pratt WR "Allergic diseases in pregnancy and breast feeding." Ann Allergy 47 (1981): 355-60
  14. Gardner MJ, Schatz M, Cousins L, Zeiger R, Middleton E, Jusko WJ "Longitudinal effects of pregnancy on the pharmacokinetics of theophylline." Eur J Clin Pharmacol 32 (1987): 289-95

References for breastfeeding information

  1. Yurchak AM, Jusko WJ "Theophylline secretion into breast milk." Pediatrics 57 (1976): 518-20
  2. Stec GP, Greenberger P, Ruo TI, et al "Kinetics of theophylline transfer to breast milk." Clin Pharmacol Ther 28 (1980): 404-8
  3. "Product Information. Theo-Dur (theophylline)." Schering Laboratories, Kenilworth, NJ.
  4. Committee on Drugs, 1992 to 1993 "The transfer of drugs and other chemicals into human milk." Pediatrics 93 (1994): 137-50
  5. Pratt WR "Allergic diseases in pregnancy and breast feeding." Ann Allergy 47 (1981): 355-60

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.